Headache & Pain

Filter Your Results

 

News

 

Lilly’s Investigational Monoclonal Antibody for Migraine Scores Positive Phase 3 Results

Friday, May 12, 2017—New Phase 3 data suggest that Eli Lilly’s investigational monoclonal antibody galcanezumab may significantly reduce the number of monthly migraine headache days. In…

FDA Releases Non-Invasive VNS Therapy for Pain Associated with Episodic Cluster Headache

Tuesday, April 18, 2017—The FDA has released the use of gammaCore, a non-invasive vagus nerve stimulator for the acute treatment of pain associated with episodic cluster headache in adult patients. g…

Small Fiber Neuropathy in Sjogren’s Syndrome: A Review

Anna Chang, BS, Kevin Lazo, DO, Michael Malekan, DO, and Steven Mandel, MD

April 2017—A lack of uniform diagnostic criteria for small fiber neuropathy and Sjogren’s syndrome presents several challenges for treatment.

FDA Approves Expanded Indication For Qudexy XR Extended Release Capsules

Thursday, March 30, 2017—The FDA has approved two supplemental indications for Qudexy XR (topiramate, Upsher-Smith) Extended Release Capsules for use as prophylaxis of migraine headache in adults and …

Review Identifies Antidepressants and AEDs Effective for Nerve Pain

Friday, March 24, 2017—A federal health agency has found certain antidepressants and anti-seizure drugs are among medications that effectively treat diabetic nerve pain. In findings published in the…

Lower Vitamin D Levels in Men Linked to Increased Frequency of Headache

Thursday, January 19, 2017—Low levels of vitamin D was associated with markedly higher risk of frequent headache in men, according to new findings published in Scientific Reports (Article number:&n…

Lilly to Acquire Migraine Drug Maker CoLucid

Wednesday, January 18, 2017—Eli Lilly and Co. is set to acquire CoLucid Pharmaceuticals for $960 million. CoLucid is currently developing lasmiditan, a migraine medicine that could help patients wit…

Calcitonin Gene-Related Peptide, Monoclonal Antibodies, and Migraine

Clinton G. Lauritsen, DO and Stephen D. Silberstein, MD

November/December 2016—The recent development of monoclonal antibodies for the treatment of migraine may have a significant impact on the field and mark a new chapter in patient care.

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.

 
  • BRYN MAWR COMMUNICATIONS III, LLC